Elderly Patients with Acute Coronary Syndromes: Higher Risk and Greater Benefit from Antithrombotic and Interventional Therapies.
In elderly patients with acute coronary syndromes, outcomes are poorer than in younger patients and, disappointingly, some therapies-including thrombolysis for ST elevation myocardial infarction-confer less benefit than in younger patients. In contrast, in unstable angina and non-ST elevation myocardial infarction, the elderly appear to derive greater relative and absolute benefit from the newer, more potent antithrombotic therapies. In both the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events and Thrombolysis in Myocardial Infarction 11B trials, the low molecular weight heparin enoxaparin, compared with unfractionated heparin, appeared to have greater relative and absolute benefit in patients aged 65 years and older, as compared with younger patients. For the glycoprotein IIb/IIIa inhibitors, an equivalent relative benefit has been observed, which translated into a greater absolute benefit in older vs. younger patients. Similarly, in the FRagmin and Fast Revascularisation during InStability in Coronary Artery Disease II trial, patients 65 years and older derived significantly greater benefit from an invasive than from a conservative strategy, whereas there was no difference in outcome by strategy in younger patients. A similar trend was observed in the Thrombolysis in Myocardial Infarction IIIB trial. Thus, in unstable angina and non-ST elevation myocardial infarction, elderly patients are at higher risk and appear to derive particular benefit from the more aggressive antithrombotic and interventional therapies. (c) 2000 by CVRR, Inc.